FDA approves Kineret(SOBI) for NOMID

Sobi- Swedish Orphan has announced that the FDA has approved Kineret (anakinra) for the treatment of children and adults with Neonatal-Onset Multisystem Inflammatory Disease (NOMID).

Kineret is the first and only FDA-approved therapy for NOMID, the most severe form of cryopyrin associated periodic syndromes (CAPS). This is the first approval allowing the use of Kineret in children. Kineret was approved for NOMID under an Orphan Drug designation. A priority review was granted by the FDA based on the product's potential to provide a significant advance in therapy for the NOMID patient population where no adequate therapy exists.

Kineret has been approved for the reduction of signs and symptoms of Rheumatoid Arthritis (RA) in adults since 2001.